Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX) from its SEC filings: 2025 revenue $62.4 million (+48% vs the year before), net margin -163%, free cash flow -$139.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $62.4 million |
| Revenue growth | +48% |
| Net income | -$101.6 million |
| Net margin | -162.9% |
| Free cash flow | -$139.9 million |
| Diluted EPS | $-0.87 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $345.6 million |
| Share count, 1 year | +52% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.